Brian Keevil (Presenter)
University hospital of South Manchester
Bio: Brian Keevil is a Consultant clinical Scientist at the University Hospital of South Manchester. He has developed a special interest in LC-MS/MS methodology over the past 15 years and using this technique has developed many methods for routine and research use in the laboratory, particularly for therapeutic drugs and steroids. He is an internationally recognised expert in the use of LC-MS/MS in the clinical laboratory. Current research interests include the use of alternative sampling strategies such as dried blood spot sampling for the measurement of drugs and salivary analysis for the measurement of free steroids. He has published more than 150 peer reviewed publications and is an honorary Professor at the University of Manchester.
Authorship: Brian Keevil
University Hospital of South Manchester
Demonstration of androgen excess is important in women but there is currently no consensus on what is the best androgen to measure. LC-MS/MS is increasingly being used in the clinical laboratory for steroid measurement particularly in multiplexed panels.
Demonstration of androgen excess is important in women but there is currently no consensus on what is the best androgen to measure. Serum testosterone has been the mainstay for assessment because it is the most potent androgen and it has gained widespread acceptance as being the best single measurement of choice for the investigation of female hyperandrogenism. However, total testosterone is not invariably elevated in PCOS and other weaker androgens such as DHEA and androstenedione may also have a role to play. However, measurement of other androgens in routine laboratories by immunoassay has not been easy because of technology constraints and cost. LC-MS/MS is increasingly being used in the clinical laboratory and it is now recognised as a superior measurement technique because of its improved detection levels and specificity. Another crucial advantage that LC-MS/MS has over immunoassay is the ability to simultaneously measure other steroids at no extra cost. This now makes it possible to measure a panel of androgens to potentially improve the diagnosis and monitoring of PCOS. This talk will focus on some of the problems with measuring androgens in PCOS, emerging technology such as salivary analysis and possible new candidate steroid markers.
Conclusions & Discussion
References & Acknowledgements:
IP Royalty: no
|Planning to mention or discuss specific products or technology of the company(ies) listed above:||